Personalis Inc. (PSNL)
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating
Personalis, Inc. is rated Buy, driven by strong momentum in its NeXT Personal Dx MRD test and recent Medicare coverage expansions. Despite a projected 2026 net loss of ~$100m and 14% revenue growth, PSNL's clinical test volume is ramping rapidly, with 43k–45k tests targeted this year. Key catalysts include expanded CMS MolDX coverage for breast and lung cancer recurrence monitoring and potential M&A interest given an $887m market cap.
Personalis Q1 Earnings Call Highlights
Personalis NASDAQ: PSNL reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business and biopharma MRD programs over lower-margin legacy enterprise revenue.
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.18 per share a year ago.
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.23 per share a year ago.
Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript
Personalis, Inc. ( PSNL ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Christopher Hall - President, CEO & Director Aaron Tachibana - CFO & COO Richard Chen - Executive VP of R&D and Chief Medical Officer Conference Call Participants Caroline Corner - Westwicke Partners, LLC Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Daniel Brennan - TD Cowen, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Michael Matson - Needham & Company, LLC, Research Division John Wilkin - Craig-Hallum Capital Group LLC, Research Division Yu He - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Personalis Third Quarter 2025 Earnings Conference.
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.64 per share a year ago.
Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?
Personalis (PSNL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)
The heavy selling pressure might have exhausted for Personalis (PSNL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)
Personalis (PSNL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy
Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
